Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

DICE Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2013 · IPO 2021 Unicorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$2.40B
Market cap · 2026

Global footprint

Where DICE Therapeutics has talent and traffic

Web traffic by country
560 monthly visits
across markets
🇺🇸 United States107.1%
Top 1 markets shown

Patent intelligence

$6M patent portfolio · 20 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value
$6M
0.27% of market cap · 35.6× smaller than top peer Galapagos ($230M)
20 active patent families
Where DICE Therapeutics innovates Pharmaceutical drugMolecular biologyUlcerative colitisIntegrinSmall molecule
Above peer median on Strategic · Below peer median on Legal, Market, Economic, Technology

Quality vs same-sector peers

DICE Therapeutics on the five Patsnap quality dimensions

DICE Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where DICE Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across DICE Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See DICE Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.